FDA Will Drop “Cycle” Goals, Prioritize Interactive Device Reviews
This article was originally published in The Gray Sheet
Executive Summary
FDA is proposing to eliminate premarket review interim "cycle" goals in order to prioritize more informal, interactive reviews and final approval decision times under a plan for reauthorization of the medical device user fee program released April 16